Dr Apar Kishor Ganti Outlines the Effectiveness of Lurbinectedin and Benefits Over Competition – AJMC.com Managed Markets Network
Posted: November 26, 2020 at 2:50 am
Lurbinectedin is being studied in a number of diseases, but in lung cancer it has a more favorable side effect profile compared with topotecan, said Apar Kishor Ganti, MD, University of Nebraska Medical Center.
Lurbinectedin is being studied in a number of diseases, but in lung cancer it has a more favorable side effect profile compared with topotecan, said Apar Kishor Ganti, MD, professor of internal medicine, Division of Oncology & Hematology, University of Nebraska Medical Center.
Are there other tumor types where lurbinectedin seems to hold promise?
So, lurbinectedin is being studied in other diseases like breast cancer, mesothelioma, chronic lymphocytic leukemia, among others. But the difference in these other conditions compared to small cell [lung cancer] is there are other treatment options that are reasonably effective in these other cancers, unlike in small cell, so that's where it becomes much more important in in this particular setting.
One other reason why lurbinectedin may be effective is, like I told you earlier, there is a group of cells that seem to be shielded from chemotherapy. We call them cancer stem cells. And there are some lab data that suggests that lurbinectedin may inhibit cancer stem cells, as well. Again, this is all preliminary data. And we don't necessarily know if that occurs in humans or not, but those are some of the hypothesized mechanisms of action.
What other advantages are there of lurbinectedin over topotecan?
One of the other advantages of lurbinectedin over topotecan is that topotecan has to be given 5 days in a row, whereas lurbinectedin is given just once every 3 weeks. And the side effect profile of lurbinectedin seems to be favorable. The main side effect of lurbinectedin is bone marrow suppression, anemia, leukopenia, neutropenia, [and] thrombocytopenia, but they seem to occur in about 5% to 10% of patients. And so, that's another possible advantage of lurbinectedin over for some of the other drugs that are available.
As far as small cell lung cancer itself is concerned, even though there is a lot of research going on in small cell, multiple different drugs have been triedtargeted therapies, immunotherapythere is some evidence to suggest that immunotherapy helps with chemotherapy in the frontline setting. But immunotherapy by itself in patients who have failed chemotherapy does not seem to be much more effective. People have tried targeted therapies, again, not one of them has shown to have any meaningful benefit for these patients. So that has been very disappointing.
There have been multiple drugs that have been studied. Unfortunately, none of them have had a significant benefit so far. So, it's a fairly difficult to treat disease. And like I mentioned earlier, even though it seems to respond quite well to initial chemotherapymost patients relapse and very few are cured even if they present with very early stage disease. And that's why it's a very challenging disease to treat.
- Unlocking The Unlimited Potential Of Stem Cells - CodeBlue - January 9th, 2021
- Hemostemix steps into the new year with capital and its critical clinical study data in hand - InvestorIntel - January 9th, 2021
- Global Organ and Tissue Transplantation and Alternatives Market to 2024 - Impact Analysis of COVID-19 - Yahoo Finance - January 9th, 2021
- Top 10 ALS Stories of 2020 - ALS News Today - January 9th, 2021
- Brave West Lothian women discovers back pain is actually deadly blood cancer - Daily Record - January 9th, 2021
- Global Bone Marrow Aspirate Concentrates (BMAC) Market : Industry Analysis and forecast (2019 to 2026): By product Type, Application, End Users, and... - January 9th, 2021
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 22nd, 2020
- Organ and Tissue Transplantation and Alternatives - GlobeNewswire - December 22nd, 2020
- How Researchers Are Making Do in the Time of COVID-19 - The Wire Science - December 22nd, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 22nd, 2020
- Priming the Immune System to Fight Cancer - PRNewswire - December 22nd, 2020
- The 11 most mind-blowing, awe-inspiring health discoveries and innovations of 2020 - Business Insider - Business Insider - December 22nd, 2020
- Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) - GlobeNewswire - December 22nd, 2020
- Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0 - December 22nd, 2020
- Digenic mutations in ALDH2 and ADH5 impair formaldehyde clearance and cause a multisystem disorder, AMeD syndrome - Science Advances - December 22nd, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - KPVI News 6 - December 16th, 2020
- Novel class of targeted cancer therapies could treat myeloid leukaemias - Drug Target Review - December 16th, 2020
- 1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive - NPR - December 16th, 2020
- Bone Regeneration Material Market: Cell-based Segment to Expand Significantly - BioSpace - December 16th, 2020
- Shingles: What triggers this painful, burning rash? - Harvard Health Blog - Harvard Health - December 16th, 2020
- Impact of Covid-19 On Orthopedic Regenerative Medicine Market Business Overview and Forecast to 2027 | Curasan, Inc., Carmell Therapeutics... - December 16th, 2020
- Early Signs of Activity and Tolerability Found in Allogeneic Product UCART22 for Patients with Relapsed/Refractory CD22+ B-Cell ALL - Cancer Network - December 16th, 2020
- Updated Findings Show Continued Efficacy for CAR T-Cell Therapy in Heavily Pretreated Myeloma - Targeted Oncology - December 16th, 2020
- Haywards Heath woman's bid to fund stem cell treatment to combat MS - Mid Sussex Times - December 16th, 2020
- Stem Cell Transplant Reduces Relapses and Disability in RRMS... - Multiple Sclerosis News Today - December 11th, 2020
- Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission... - December 11th, 2020
- Groundbreaking Trial On Children With Brain Injuries In Madrid - Euro Weekly News - December 11th, 2020
- Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting - Yahoo Finance - December 11th, 2020
- Antileukemic Activity Seen With Flotetuzumab in Primary Induction Failure, Early-Relapse AML - Hematology Advisor - December 11th, 2020
- SNUH finds way to produce T-cells to prevent HSCT complications - Korea Biomedical Review - December 11th, 2020
- CLL patients in England to get AZ's Calquence after okay from NICE - - pharmaphorum - December 11th, 2020
- JP Duminy goes to bat for the SA Bone Marrow Registry - IOL - December 10th, 2020
- Donor Stem Cell Transplant Improves Survival in Older Patients with Myelodysplastic Syndrome - Cancer Health Treatment News - December 10th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - Business Wire - December 10th, 2020
- Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID... - December 10th, 2020
- Bid to fund stem cell treatment in Mexico for woman with MS - Bournemouth Echo - December 10th, 2020
- The Technology Behind Bone Marrow Cellular Processing: The PXP System - Marketscreener.com - December 10th, 2020
- ElevateBio's HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting - Business Wire - December 10th, 2020
- Gene Therapy, Absolutely and For Real | In the Pipeline - Science Magazine - December 10th, 2020
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 10th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - PRNewswire - December 10th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 10th, 2020
- Hadassah Medical Center and Neurogenesis Announce Groundbreaking Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01... - December 10th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 10th, 2020
- Venetoclax/Azacitidine Combination Efficacious for the Treatment of Older Patients With Higher-Risk Myelodysplastic Syndrome - Oncology Nurse Advisor - December 10th, 2020
- Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T at the 62nd ASH Annual Meeting... - December 10th, 2020
- BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium - BioSpace - December 10th, 2020
- Joliet 2-year-old gets pre-holiday gift: tests that show he's cancer-free - The Herald-News - December 10th, 2020
- Preliminary Results from NexImmune's Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition - GlobeNewswire - December 10th, 2020
- How do you donate stem cells? Donating cells can help treat cancer, blindness and other conditions - heres how - The Scotsman - December 4th, 2020
- Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price - Being Patient - December 4th, 2020
- Treatment to restore vision by injecting stem cells into the eye could help people with damaged eyesight - iNews - December 4th, 2020
- Sphingosine 1-phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated... - December 4th, 2020
- Cancer center is a contributor to 49 research studies at the 62nd American Society of Hematology Annual Meeting - Newswise - December 4th, 2020
- IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bios Gamma Delta T-cell product... - December 4th, 2020
- Bone Marrow Transplant Market Size, Segmented by Type of Deployment, Application, And Region Growth, Trends, And Forecast - The Haitian-Caribbean... - December 4th, 2020
- Gut bacteria can help rebuild the immune system - Medical News Today - December 4th, 2020
- InvestmentPitch Media Video Discusses Hemostemix Successfully Obtaining all Clinical Trial Data and Announcement of $2.5 Million Unit Offering - Video... - December 4th, 2020
- Outlook on the Multiple Myeloma Drugs Global Market to 2025 - by Therapy, Drug Type, End-user, Distribution Channel and Region -... - December 4th, 2020
- Imago BioSciences Expands Phase 2 Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong - Business Wire - December 4th, 2020
- The New Coronavirus Vaccine Is Changing The Future Of Medicine - Forbes - December 4th, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - November 30th, 2020
- How are bones and the heart connected? - British Heart Foundation - November 30th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - November 30th, 2020
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 Impact of COVID-19, Future Growth Analysis and Challenges | Regen Biopharma Inc,... - November 30th, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - November 30th, 2020
- Hematopoietic Stem Cell Transplantation (HSCT) Market To Witness Huge Growth By 2027 | Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc,... - November 30th, 2020
- Bone Marrow Processing Systems Market Top Participant to Focus on Regional Expansion - Murphy's Hockey Law - November 30th, 2020
- Family 'over the moon' as nine-year-old Aurora confirmed as being back in remission - The Isle of Thanet News - November 30th, 2020
- Pilot study finds potential signal indicative of loss of tone in blood vessels after cardiac surgery - The Hindu - November 30th, 2020
- Family's joy as schoolgirl, 9, back in remission - Kent Online - November 30th, 2020
- Family's heartache after Hebburn boy diagnosed with one in a million condition - Chronicle Live - November 30th, 2020
- Raleigh man delivers stem cells to patients around the world - WRAL.com - November 28th, 2020
- US FDA Approves Naxitamab for the Treatment of Neuroblastoma - OncoZine - November 28th, 2020
- The roles bone marrow plays in the body - Therogersvillereview - November 27th, 2020
- Severe Infections Wreak Havoc on Mouse Blood Cell Production - Technology Networks - November 27th, 2020
- Revenue from the Sales of Hematopoietic Stem Cells Transplantation Market to Witness Relatively Significant Growth During 2017 2025 - Canaan Mountain... - November 27th, 2020
- Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for... - November 27th, 2020
- Meet 'Iron Boy': Hempfield Twp. boy fighting cancer is real superhero - Gettysburg Times - November 27th, 2020
- G1 Therapeutics: Depressed Price Before Catalyst, No Apparent Reason - Seeking Alpha - November 27th, 2020